Public-registry site landscape for NCT04113616, a Relapsed or Refractory Acute Myeloid Leukemia (AML) study sponsored by Kartos Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04113616 (registry record) |
| Sponsor | Kartos Therapeutics, Inc. |
| Condition(s) | Relapsed or Refractory Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 59 |
| Site countries | United States, Australia, Belgium, France, Germany, Hungary, Israel, Italy, Poland, South Korea, Spain, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT04113616 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →